Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer ; volume:56 ; number:5 ; day:1 ; month:5 ; year:2024 ; pages:1137-1149 ; date:5.2024
Experimental & molecular medicine ; 56, Heft 5 (1.5.2024), 1137-1149, 5.2024

Creator: Park, Wonyoung
Wei, Shibo
Xie, Chu-Long
Han, Jung Ho
Kim, Bo-Sung
Kim, Bosung
Jin, Jung-Sook
Yang, Eun-Sun
Cho, Min Kyoung
Ryu, Dongryeol
Yang, Hao-Xian
Bae, Sung-Jin
Ha, Ki-Tae

Contributor: SpringerLink (Online service)

DOI: 10.1038/s12276-024-01221-2

URN: urn:nbn:de:101:1-2408102121589.121074817310

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Park, Wonyoung
Wei, Shibo
Xie, Chu-Long
Han, Jung Ho
Kim, Bo-Sung
Kim, Bosung
Jin, Jung-Sook
Yang, Eun-Sun
Cho, Min Kyoung
Ryu, Dongryeol
Yang, Hao-Xian
Bae, Sung-Jin
Ha, Ki-Tae
SpringerLink (Online service)

Other Objects (12)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Hochschulschrift

Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells

Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Hochschulschrift

Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells

Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Hochschulschrift

Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells

Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells

Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells

Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells

Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Related objects

Reset password